Amneal Pharmaceuticals is paying $375 million upfront for a biosimilar company, in a deal that could ultimately cost more if milestone payments kick in. No per-share price has been disclosed, making it hard to pin down what premium Amneal is paying.
What does Amneal actually get? That’s the question. Biosimilar deals typically hinge on a lead product’s clinical stage and peak-sales projections. Neither figure is available in publicly accessible reporting, which is unusual for a $375M commitment. Amneal already runs a biosimilars portfolio, so this reads as a portfolio add rather than a platform play, but the strategic logic depends on assets nobody’s named. Without those figures, the deal is difficult to evaluate on its merits.
The “upfront” qualifier leaves room for the total to run well above $375M. How far above depends on milestones that won’t be public until the deal closes. Milestone structures in pharma can push total consideration well above headline figures, and this deal’s terms have not been disclosed.
Diana Kowalski